US FDA Actions On Rx Drug Promos Covered New Territory Last Year

Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.

2020-2021 PINK SHEET PERSPECTIVES - Megaphone
FDA issued fewer Rx drug promo enforcement letters in 2020 while initiating six new research projects • Source: Shutterstock

More from Marketing & Advertising

More from Compliance